Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo controlled Study of the Steroid Sulfatase Inhibitor PGL2001 with concomitant administration of NETA (norethisterone acetate) for the treatment of symptoms related to endometriosis

X
Trial Profile

A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo controlled Study of the Steroid Sulfatase Inhibitor PGL2001 with concomitant administration of NETA (norethisterone acetate) for the treatment of symptoms related to endometriosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PGL 2 (Primary) ; Norethisterone
  • Indications Endometriosis
  • Focus Therapeutic Use
  • Acronyms AMBER
  • Sponsors PregLem
  • Most Recent Events

    • 02 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Additional trial location (Romania) added as reported by ClinicalTrials.gov: US National Institutes of Health.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top